Potentiation of methoxymorpholinyl doxorubicin antitumor activity by P450 3A4 gene transfer

Cancer Gene Therapy

Volumn 16, Issue 5, 2009, Pages 393-404

  Lu, H ^a   Chen, C S ^a   Waxman, D J ^a  

^a Boston University   (United States)

Author keywords

CYP3A4; Gene directed enzyme prodrug therapy; Methoxymorpholinyl doxorubicin; Nemorubicin; Prodrug activation gene therapy

Indexed keywords

ADENOVIRUS VECTOR; CONDITIONALLY REPLICATING ADENOVIRUS; CYTOCHROME P450 3A4; CYTOCHROME P450 REDUCTASE; DRUG METABOLITE; IFOSFAMIDE; NEMORUBICIN; ONYX 017; RETROVIRUS VECTOR; RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN TUMOR; CANCER CELL; CANCER PATIENT; CHEMOSENSITIVITY; CHO CELL; CONTROLLED STUDY; DRUG POTENTIATION; FIRST PASS EFFECT; GENE DIRECTED ENZYME PRODRUG THERAPY; GENE EXPRESSION; GLIOSARCOMA; GROWTH RETARDATION; HUMAN; HUMAN CELL; LOW DRUG DOSE; LUNG TUMOR; MALE; MIXED INFECTION; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT RESPONSE; VIRAL GENE DELIVERY SYSTEM; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CHO CELLS; CRICETINAE; CRICETULUS; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DOXORUBICIN; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; IFOSFAMIDE; MICE; NEOPLASMS; RETROVIRIDAE; TRANSFECTION;

ADENOVIRIDAE; MUS; ONYX;

EID: 65049088393     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2008.93     Document Type: Article

References (57)

1. Michael M, Doherty MM. Tumoral drug metabolism: overview and its implications for cancer therapy. J Clin Oncol 2005; 23: 205-229.
2. Moolten FL. Drug sensitivity ('suicide') genes for selective cancer chemotherapy. Cancer Gene Ther 1994; 1: 279-287.
3. Roy P, Waxman DJ. Activation of oxazaphosphorines by cytochrome P450: application to gene-directed enzyme prodrug therapy for cancer. Toxicol In Vitro 2006; 20: 176-186.
4. Chen L, Yu LJ, Waxman DJ. Potentiation of cytochrome P450/ cyclophosphamide-based cancer gene therapy by coexpression of the P450reductase gene. Cancer Res 1997; 57: 4830-4837.
5. Chase M, Chung RY, Chiocca EA. An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy. Nat Biotechnol 1998; 16: 444-448.
6. Jounaidi Y, Chen CS, Veal GJ, Waxman DJ. Enhanced antitumor activity of ,P450prodrug-based gene therapy using the low Km cyclophosphamide 4-hydroxylase P4502B11. Mol Cancer Ther 2006; 5: 541-555.
7. Jounaidi Y, Hecht JE, Waxman DJ. Retroviral transfer of human cytochrome P450genes for oxazaphosphorine-based cancer gene therapy. Cancer Res 1998; 58: 4391-4401.
8. Tyminski E, Leroy S, Terada K, Finkelstein DM, Hyatt JL, Danks MK et al. Brain tumor oncolysis with replicationconditional herpes simplex virus type 1 expressing the prodrug-activating genes, CYP2B1 and secreted human intestinal carboxylesterase, in combination with cyclophosphamide and irinotecan. Cancer Res 2005; 65: 6850-6857.
9. Niculescu-Duvaz I, Springer CJ. Introduction to the background, principles, and state of the art in suicide gene therapy. Mol Biotechnol 2005; 30: 71-88.
10. Zhang Y, Parker WB, Sorscher EJ, Ealick SE. PNP anticancer gene therapy. Curr Top Med Chem 2005; 5: 1259-1274.
11. Searle PF, Chen MJ, Hu L, Race PR, Lovering AL, Grove JI et al. Nitroreductase: a prodrug-activating enzyme for cancer gene therapy. Clin Exp Pharmacol Physiol 2004; 31: 811-816.
12. Trask TW, Trask RP, Aguilar-Cordova E, Shine HD, Wyde PR, Goodman JC et al. Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors. Mol Ther 2000; 1: 195-203.
13. Cunningham C, Nemunaitis J. A phase I trial of genetically modified Salmonella typhimurium expressing cytosine deaminase (TAPET-CD, VNP20029) administered by intratumoral injection in combination with 5-fluorocytosine for patients with advanced or metastatic cancer. Protocol no: CL-017. Version: April 9, 2001. Hum Gene Ther 2001; 12: 1594-1596.
14. Freytag SO, Strieker H, Peabody J, Pegg J, Paielli D, Movsas B et al. Five-year follow-up of trial of replication-competent adenovirus-mediated suicide gene therapy for treatment of prostate cancer. Mol Ther 2007; 15: 636-642.
15. Braybrooke JP, Slade A, Deplanque G, Harrop R, Madhusudan S, Forster MD et al. Phase I study of MetXiaF450gene therapy and oral cyclophosphamide for patients with advanced breast cancer or melanoma. Clin Cancer Res 2005; 11: 1512-1520.
16. Chen L, Waxman DJ. Intratumoral activation and enhanced chemotherapeutic effect of oxazaphosphorines following cytochrome P-450 gene transfer: development of a combined chemotherapy/cancer gene therapy strategy. Cancer Res 1995; 55: 581-589.
17. Samel S, Keese M, Lux A, Jesnowski R, Prosst R, Sailer R et al. Peritoneal cancer treatment with CYP2B1 transfected, microencapsulated cells and ifosfamide. Cancer Gene Ther 2006; 13: 65-73.
18. Jounaidi Y, Waxman DJ. Combination of the bioreductive drug tirapazamine with the chemotherapeutic prodrug cyclophosphamide for P450/P450-reductase-based cancer gene therapy. Cancer Res 2000; 60: 3761-3769.
19. McCarthy HO, Yakkundi A, McErlane V, Hughes CM, Keilty G, Murray M et al. Bioreductive GDEPT using cytochrome P4503A4 in combination with AQ4N. Cancer Gene Ther 2003; 10: 40-48.
20. Ghielmini M, Colli E, Bosshard G, Pennella G, Geroni C, Torri V et al. Hematotoxicity on human bone marrow- and umbilical cord blood-derived progenitor cells and in vitro therapeutic index of methoxymorpholinyldoxorubicin and its metabolites. Cancer Chemother Pharmacol 1998; 42: 235-240.
21. Kuhl JS, Duran GE, Chao NJ, Sikic BI. Effects of the methoxymorpholino derivative of doxorubicin and its bioactivated form versus doxorubicin on human leukemia and lymphoma cell lines and normal bone marrow. Cancer Chemother Pharmacol 1993; 33: 10-16.
22. Lau DH, Duran GE, Lewis AD, Sikic BI. Metabolic conversion of methoxymorpholinyl doxorubicin: from a DNA strand breaker to a DNA cross-linker. Br J Cancer 1994; 70: 79-84.
23. Lewis AD, Lau DH, Duran GE, WoIf CR, Sikic BI. Role of cytochrome P-450 from the human CYP3A gene family in the potentiation of morpholino doxorubicin by human liver microsomes. Cancer Res 1992; 52: 4379-4384.
24. Baldwin A, Huang Z, Jounaidi Y, Waxman DJ. Identification of novel enzyme-prodrug combinations for use in cytochrome P450-based gene therapy for cancer. Arch Biochem Biophys 2003; 409: 197-206.
25. Quintieri L, Geroni C, Fantin M, Battaglia R, Rosato A, Speed W et al. Formation and antitumor activity of PNU-159682, a major metabolite of nemorubicin in human liver microsomes. Clin Cancer Res 2005; 11: 1608-1617.
26. Alvino E, Gilberti S, Cantagallo D, Massoud R, Gatteschi A, Tentori L et al. In vitro antitumor activity of 3'-desamino3'(2-methoxy-4- morpholinyl) doxorubicin on human melanoma cells sensitive or resistant to triazene compounds. Cancer Chemother Pharmacol 1997; 40: 180-184.
27. Lu H, Waxman DJ. Antitumor activity of methoxymorpholinyl doxorubicin: potentiation by cytochrome P4503A metabolism. Mol Pharmacol 2005; 67: 212-219.
28. Quintieri L, Rosato A, Napoli E, Sola F, Geroni C, Floreani M et al. In vivo antitumor activity and host toxicity of methoxymorpholinyl doxorubicin: role of cytochrome P4503A. Cancer Res 2000; 60: 3232-3238.
29. Ding S, Yao D, Burchell B, Wolf CR, Friedberg T. High levels of recombinant CYP3A4 expression in Chinese hamster ovary cells are modulated by coexpressed human P450reductase and hemin supplementation. Arch Biochem Biophys 1997; 348: 403-410.
30. Kozak M. Point mutations define a sequence flanking the AUG initiator codon that modulates translation by eukaryotic ribosomes. Cell 1986; 44: 283-292.
31. Finer MH, Dull TJ, Qin L, Farson D, Roberts MR. kat: a high-efficiency retroviral transduction system for primary human T lymphocytes. Blood 1994; 83: 43-50.
32. Chen CS, Jounaidi Y, Waxman DJ. Enantioselective metabolism and cytotoxicity of R-ifosfamide and S-ifosfamide by tumor cell-expressed cytochromes P450. Drug Metab Dispos 2005; 33: 1261-1267.
33. Miwa GT, West SB, Lu AY. Studies on the rate-limiting enzyme component in the microsomal monooxygenase system. Incorporation of purified NADPH-cytochrome c reductase and cytochrome P-450 into rat liver microsomes. J Biol Chem 1978; 253: 1921-1929.
34. Jounaidi Y, Waxman DJ. Use of replication-conditional adenovirus as a helper system to enhance delivery of P450prodrug-activation genes for cancer therapy. Cancer Res 2004; 64: 292-303.
35. Kivisto KT, Kroemer HK, Eichelbaum M. The role of human cytochrome P450enzymes in the metabolism of anticancer agents: implications for drug interactions. Br J Clin Pharmacol 1995; 40: 523-530.
36. Haaz MC, Rivory L, Riche C, Vernillet L, Robert J. Metabolism of irinotecan (CPT-Il) by human hepatic microsomes: participation of cytochrome P-450 3A and drug interactions. Cancer Res 1998; 58: 468-472.
37. Yao D, Ding S, Burchell B, Wolf CR, Friedberg T. Detoxication of vinca alkaloids by human P450CYP3A4- mediated metabolism: implications for the development of drug resistance. J Pharmacol Exp Ther 2000; 294: 387-395.
38. Chen L, Waxman DJ. Cytochrome P450gene-directed enzyme prodrug therapy (GDEPT) for cancer. Curr Pharm Des 2002; 8: 1405-1416.
39. Salmons B, Lohr M, Gunzburg WH. Treatment of inoperable pancreatic carcinoma using a cell-based local chemotherapy: results of a phase I/I.I clinical trial. J Gastroenterol 2003; 38(Suppl 15): 78-84.
40. Martinez C, Garcia-Martin E, Pizarro RM, Garcia-Gamito FJ, Agundez JA. Expression of paclitaxel-inactivating CYP3A activity in human colorectal cancer: implications for drug therapy. Br J Cancer 2002; 87: 681-686.
41. Schmidt R, Baumann F, Knupfer H, Brauckhoff M, Horn LC, Schönfelder M et al. CYP3A4, CYP2C9 and CYP2B6 expression and ifosfamide turnover in breast cancer tissue microsomes. Br J Cancer 2004; 90: 911-916.
42. Kivisto KT, Fritz P, Linder A, Friedel G, Beaune P, Kroemer HK. Immunohistochemical localization of cytochrome P4503A in human pulmonary carcinomas and normal bronchial tissue. Histochem Cell Biol 1995; 103: 25-29.
43. Murray GI, McFadyen MC, Mitchell RT, Cheung YL, Kerr AC, Melvin WT. Cytochrome P450CYP3A in human renal cell cancer. Br J Cancer 1999; 79: 1836-1842.
44. Murray GI, Taylor VE, McKay JA, Weaver RJ, Ewen SW, Melvin WT et al. Expression of xenobiotic metabolizing enzymes in tumours of the urinary bladder. Int J Exp Pathol 1995; 76: 271-276.
45. Engels FK, Ten Tije AJ, Baker SD, Lee CK, Loos WJ, Vulto AG et al. Effect of cytochrome P4503A4 inhibition on the pharmacokinetics of docetaxel. Clin Pharmacol Ther 2004; 75: 448-454.
46. Crespi CL, Penman BW, Hu M. Development of Caco-2 cells expressing high levels of cDNA-derived cytochrome P4503A4. Pharm Res 1996; 13: 1635-1641.
47. Yoshitomi S, Ikemoto K, Takahashi J, Miki H, Namba M, Asahi S. Establishment of the transformants expressing human cytochrome P450subtypes in HepG2, and their applications on drug metabolism and toxicology. Toxicol In Vitro 2001; 15: 245-256.
48. Lengler J, Omann M, Duvier D, Holzmüller H, Gregor W, Salmons B et al. Cytochrome P450reductase dependent inhibition of cytochrome P4502B1 activity: implications for gene directed enzyme prodrug therapy. Biochem Pharmacol 2006; 72: 893-901.
49. Kaminsky LS, Guengerich FP. Cytochrome P-450 isozyme/ isozyme functional interactions and NADPH-cytochrome P450 reductase concentrations as factors in microsomal metabolism of warfarin. Eur J Biochem 1985; 149: 479-489.
50. Shimada T, Mernaugh RL, Guengerich FP. Interactions of mammalian cytochrome P450, NADPH-cytochrome P450reductase, and cytochrome b(5) enzymes. Arch Biochem Biophys 2005; 435: 207-216.
51. Vasey PA, Bissett D, Strolin-Benedetti M, Poggesi I, Breda M, Adams L et al. Phase I clinical and pharmacokinetic study of 3'-deamino-3'-(2- methoxy-4-morpholinyl)doxorubicin (FCE 23762). Cancer Res 1995; 55: 2090-2096.
52. Zangar RC, Bollinger N, Verma S, Karin NJ, Lu Y. The nuclear factor-kappa B pathway regulates cytochrome P4503A4 protein stability. Mol Pharmacol 2008; 73: 1652-1658.
53. Chen CS, Jounaidi Y, Su T, Waxman DJ. Enhancement of intratumoral cyclophosphamide pharmacokinetics and antitumor activity in a P4502B11-based cancer gene therapy model. Cancer Gene Ther 2007; 14: 935-944.
54. Ichikawa T, Petros WP, Ludeman SM, Fangmeier J, Hochberg FH, Colvin OM et al. Intraneoplastic polymer-based delivery of cyclophosphamide for intratumoral bioconversion by a replicating oncolytic viral vector. Cancer Res 2001; 61: 864-868.
55. Duvillard C, Polycarpe E, Romanet P, Chauffert B. [Intratumoral chemotherapy: experimental data and applications to head and neck tumors]. Ann Otolaryngol Chir Cervicofac 2007; 124: 53-60.
56. Celikoglu F, Celikoglu SI, Goldberg EP. Bronchoscopic intratumoral chemotherapy of lung cancer. Lung Cancer 2008; 61: 1-12.
57. Almond BA, Hadba AR, Freeman ST, Cuevas BJ, York AM, Detrisac CJ et al. Efficacy of mitoxantroneloaded albumin microspheres for intratumoral chemotherapy of breast cancer. J Control Release 2003; 91: 147-155.